Making the financial case:
"This is going to sound silly,” he says. “The hardest part isn’t necessarily the refactoring. The hardest part is convincing people to do this. Because, let’s be honest the upfront cost can be very scary, man. It can be frightening. The business is going to say, ‘We just put in X amount of dollars last year to support these kinds of environments.’ You kind of have to ask the question, what’s going to happen five years from now?
Link: Assessing IBM i’s Role In Digital Transformation
Making the financial case:
"This is going to sound silly,” he says. “The hardest part isn’t necessarily the refactoring. The hardest part is convincing people to do this. Because, let’s be honest the upfront cost can be very scary, man. It can be frightening. The business is going to say, ‘We just put in X amount of dollars last year to support these kinds of environments.’ You kind of have to ask the question, what’s going to happen five years from now?
FDA wants to regular off-label use of ML-driven devices
Obtaining FDA approval can be a difficult and long process. “The traditional paradigm of medical device regulation was not designed for adaptive AI or ML technologies, which have the potential to adapt and optimize device performance in real – time to continuously improve healthcare for patients,” the report said. “The highly iterative, autonomous, and adaptive nature of these tools requires a new, total product lifecycle (TPLC) regulatory approach that facilitates a rapid cycle of product improvement and allows these devices to continually improve while providing effective safeguards.
FDA wants to regular off-label use of ML-driven devices
Obtaining FDA approval can be a difficult and long process. “The traditional paradigm of medical device regulation was not designed for adaptive AI or ML technologies, which have the potential to adapt and optimize device performance in real – time to continuously improve healthcare for patients,” the report said. “The highly iterative, autonomous, and adaptive nature of these tools requires a new, total product lifecycle (TPLC) regulatory approach that facilitates a rapid cycle of product improvement and allows these devices to continually improve while providing effective safeguards.
FDA wants to regular off-label use of ML-driven devices
Obtaining FDA approval can be a difficult and long process. “The traditional paradigm of medical device regulation was not designed for adaptive AI or ML technologies, which have the potential to adapt and optimize device performance in real – time to continuously improve healthcare for patients,” the report said. “The highly iterative, autonomous, and adaptive nature of these tools requires a new, total product lifecycle (TPLC) regulatory approach that facilitates a rapid cycle of product improvement and allows these devices to continually improve while providing effective safeguards.
Link: Why Uber’s Business Model May Not Be Viable
The sharing economy, fueled by the internet’s capacity to match small buyers and sellers, looks like a revolutionary business model. But for this model to be sustained, there must be a reliable source of long-term profits. Ride-hailing is perhaps the application of the sharing economy that is currently most developed, so its success or failure will teach us a great deal about the model’s viability in the global business landscape. At some point, you have to make a profit.
Link: Why Uber’s Business Model May Not Be Viable
The sharing economy, fueled by the internet’s capacity to match small buyers and sellers, looks like a revolutionary business model. But for this model to be sustained, there must be a reliable source of long-term profits. Ride-hailing is perhaps the application of the sharing economy that is currently most developed, so its success or failure will teach us a great deal about the model’s viability in the global business landscape. At some point, you have to make a profit.
Link: SUSE on Cloud 9 for love-in with OpenStack and Kubernetes
> With the Cloud Application Platform 1.4, SUSE has set its sights on a multi-cloud world laying claim to being the first software distribution to go 100 per cent Kubernetes for Cloud Foundry. > > ... > > The juice comes from Cloud Foundry's Project Eirini, which allows devs to seamlessly switch between Kubernetes or Cloud Foundry Diego as their container scheduler. An organisation already invested in the Kubernetes world therefore does not have to faff around with the Cloud Foundry Application Runtime orchestration.
Link: SUSE on Cloud 9 for love-in with OpenStack and Kubernetes
> With the Cloud Application Platform 1.4, SUSE has set its sights on a multi-cloud world laying claim to being the first software distribution to go 100 per cent Kubernetes for Cloud Foundry. > > ... > > The juice comes from Cloud Foundry's Project Eirini, which allows devs to seamlessly switch between Kubernetes or Cloud Foundry Diego as their container scheduler. An organisation already invested in the Kubernetes world therefore does not have to faff around with the Cloud Foundry Application Runtime orchestration.
Link: Pivotal Cloud Foundry 2.5, Now GA, Harnesses the Power of Istio and Envoy to Make Your Developers More Productive
Whole lotta features: > - Weighted routing uses Istio and Envoy to simplify blue-green deployments (beta) > - Platform Automation for PCF, the engine of your perpetual upgrade machine (beta) > - Windows Server 2019, Microsoft’s most container-friendly OS yet, now powers PAS for Windows (coming soon) > - Consume upstream Kubernetes your way with the new PKS family > - Got apps that need multiple custom ports? Run ‘em on PAS.